Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis

Abstract

Background: In the present study, we performed this meta-analysis to estimate the association between excision repair cross-complementation group 1 (ERCC1) gene polymorphism and clinical resistance to platinum-based chemotherapy in the patients with epithelial ovarian cancer (EOC).

Methods: A total of 10 studies consist of 1479 EOC patients relating ERCC1 rs11615C/T and rs3212986C/A polymorphisms to the response of platinum-based chemotherapy were included in this meta-analysis.

Results: The analysis showed that the AA genotype of the rs3212986C/A polymorphism in ERCC1 was associated with progression-free survival of EOC patients (HR = 1.39, 95% CI = 1.12–1.73) and that the CA or AA genotypes could influence overall survival (HR = 1.28, 95% CI = 1.05–1.56; and HR = 1.55, 95% CI = 1.17∼2.05, respectively).

Conclusions: The ERCC1 rs3212986C/A polymorphism may be a useful prognostic marker in platinum-based treatment of EOC.

• Clinical outcome
• epithelial ovarian cancer
• ERCC1
• meta-analysis
• platinum chemotherapy
• polymorphism